Company Profile

HYCOR Biomedical Inc (AKA: Hybridoma Sciences Inc)
Profile last edited on: 9/12/22      CAGE: 55663      UEI:

Business Identifier: Diagnostic instruments and reagents systems manufacturer, in vitro diagnostics.
Year Founded
1981
First Award
1984
Latest Award
1987
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7272 Chapman Avenue
Garden Grove, CA 92841
   (800) 382-2527
   N/A
   www.hycorbiomedical.com
Location: Single
Congr. District: 47
County: Orange

Public Profile

Originally - and very early - SBIR involved as Hybridoma Sciences, in August 1986 the firm was renamed HYCOR Biomedical Inc. In the business of manufacturing and marketing in vitro diagnostics products - and with no susbequent SBIR involvement - the firm went on to collaborate with various other players, offering allergy and autoimmune testing products and also providing AUTOSTAT kits enzyme-linked immuno sorbent assay used for detecting autoimmune disorders. Serving clinical laboratories, hospitals, and doctor’s offices in Germany and internationally, the firm is headquartered in Indianapolis, IN with additional offices in Garden Grove, CA; and Kassel, Germany. HYCOR Biomedical Inc. is a former subsidiary of Stratagene Corporation. As a vehicle to take itself public, in 2003 Stratagene (tools for the life sciences/research market) undertook a reverse merge with Hycor Biomedical. In 2013, Hycor Biomedical sold its urinalysis business to an affiliate of One Rock Capital Partners, Laurel Crown Partners, and StoneCreek Capital.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
150-249
Revenue Range
15M-20M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1987 2 NIH $510,616
Project Title: Monoclonal Antibodies to Apolipoprotein A-1
1986 2 NIH $513,184
Project Title: Monoclonal Antibodies to Erthropoiein
1984 1 NIH $48,741
Project Title: Quantitation of Glycosylated Hemoglobin by Immunoassay
1984 1 NIH $50,000
Project Title: Development of a HAT-Sensitive Human Myeloma Cell Line
1984 1 NIH $50,000
Project Title: In Vitro System for Isolating and Growing Cancer Cells

Key People / Management

  Fei Li -- President and CEO

  Daniel B Cawley

  Tommy Chiu -- Vice President of Operations

  Thomas J Foley

  Steve Gorlin

  Rich Hockins -- Senior VP Commercial Operations

  Victor Miller -- CFO

  Paul J Price

Company News

There are no news available.